Microglial activation plays a crucial role in the pathology of ischemic stroke.
Introduction
Ischemic stroke has a high clinical incidence, usually leading to severe motor dysfunction.
Pathophysiologically, it is accompanied by blood-brain-barrier (BBB) disruption, neuron loss, microglial activation, and glia scar formation (Khoshnam et al., 2017) . In the short-term, stability of the disrupted BBB and blockade of inflammatory cell infiltration have pivotal roles in protecting against neuronal loss. Long-term, angiogenesis is crucial for cerebral ischemic rehabilitation as it directly stimulates the establishment of collateral circulation.
Targets at these pathophysiological sites have been studied in animal experiments to maximize the functional recovery after cerebral ischemic stroke (Patel and McMullen, 2017) .
Microglial activation is crucial to neuroinflammation during the cerebral ischemic process, especially in the peri-infarct area . Activated microglia display two distinctive functional phenotypes. These are defined as the M1-(classical/pro-inflammatory activation) and M2-(alternative/anti-inflammatory activation) types, similar to what is found in macrophages. The balance between classically and alternatively activated microglial phenotypes influences disease progression in the central nervous system (CNS) (Jha et al., 2016; Qin et al., 2019) . Fingolimod (FTY720), an anti-inflammatory sphingosine 1-phosphate receptor (S1PR) modulator, is thought to inhibit inflammation in the CNS by acting on S1PRs that modulate lymphocyte trafficking (principally S1PR1), and that have direct effects on other inflammatory and nerve cells (Mehling et al., 2011) . In previous studies, FTY720 was used in 5 animal models of extensive neurological diseases, such as Alzheimer's disease (Jesko et al., 2018) , Parkinson's disease (Motyl et al., 2018) , white matter disease , and cerebral ischemic stroke (Liu et al., 2013) . FTY720 has been verified to mediate microglial activation (Czech et al., 2009; Moon et al., 2015) and to influence endothelial cells (ECs) . Recently, we revealed its neuro-protective ability in cortical ischemic stroke (Li et al., 2017) and white matter ischemic damage induced by chronic hypoperfusion . In the white matter injury model, demyelination was ameliorated by FTY720 by modulating microglia toward M2 polarization via the signal transducer and activator of transcription 3 pathway. However, it remains unclear whether FTY720 has a direct or indirect influence on angiogenesis during cerebral ischemia. Here, using a murine model of photothrombotic (PT) stroke to mimic cortical ischemic stroke, we investigated the influence of FTY720 on blood vessel growth in response to cerebral ischemia.
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Results
FTY720 partly ablated cortical ischemic damage induced by PT and improved motor dysfunction
To observe the effects of FTY720 on ischemic stroke damage induced by PT, Nissl staining was used to assess neuronal loss at different time points after ischemia. Consistent with our previous reports that FTY720 reduced infarct size after ischemic stroke (Li et al., 2017) , more neurons were significantly preserved in cortical ischemic lesions in the FTY720 group at days 7 and 14 compared to the vehicle group ( Fig. 1A,B ). No significant difference was found in neuron counts in the FTY720 group between days 7 and 14.
Neurological deficits caused by neuron loss after ischemic stroke were measured by the modified neurological severity score. The results showed a significant improvement in the FTY720-treated group compared to the control group, mainly at day 7 post-stroke. The improvement remained steady till day 14 (Fig. 1C ).
FTY720 skewed microglial polarization toward the M2 phenotype and alleviated neuroinflammation during PT stroke
To determine whether FTY720 modulated neuroinflammation mediated by microglial activation during PT stroke, as described in our recent report , we assessed the microglial polarization state after PT cerebral ischemia using immunohistochemistry and western blotting. We double-labeled cells for Iba-1 and the M1 marker, CD16/32, or the M2 marker, CD206, to characterize the microglial polarization state at different time points (days 7 1, 7, and 14) in peri-infarct cortices. Relative to the sham group, both CD16/32+Iba-1+ and CD206+Iba-1+ cell counts were elevated in the vehicle group at different time points, revealing apparent neuro-inflammation around the ischemic lesion. At day 7, CD16/32+Iba-1+ cells were significantly decreased and CD206+Iba-1+ cells increased in the FTY720 treatment group. Significant changes were not observed at days 1 and 14 between the vehicle and FTY720 treatment groups. Overall, Iba1+ cells in peri-infarct cortices showed tendencies similar to those of CD206+Iba1+ cells ( Fig. 2A,B ).
Western blot analysis showed that the expression of M1 markers, including iNOS and CD16, was significantly increased after PT ischemia compared to in the sham group. However, these increases were markedly attenuated in the FTY720-treated group after PT stroke compared to the vehicle group (p < 0.01) ( Fig. 2C, D) . Similarly, expression of the M2 markers, CD206
and Arg-1, was up-regulated after injury. However, the increase in M2 markers was significantly more in the FTY720 compared to the vehicle group, especially 7 days after stroke ( Fig. 2C, D) .
To assess the direct effect of FTY720 on microglial polarization, primary cultured microglia were incubated with LPS + IFN-γ, or IL-4, to induce M1 and M2 states, respectively. When treated with FTY720, expression of the M1 markers (CD16 and iNOS) was down-regulated in activated microglia in vitro, whereas that of M2 markers (CD206 and Arg-1) was up-regulated ( Fig. 3 ). These in vivo and in vitro results indicated that FTY720 treatment could skew microglial polarization directly to the M2 phenotype.
FTY720 promoted angiogenesis in the ischemic boundary zone during PT stroke
The effect of FTY720 on ECs has been studied previously, mainly focusing on short-term protection of BBB integrity and reduction of the pro-inflammatory interaction of lymphocytes with ECs and platelets, subsequently decreasing neutrophil infiltration and lymphocyte recruitment (Gaire et al., 2018; Kraft et al., 2013; Nussbaum et al., 2015; . Here, we investigated whether daily FTY720 treatment would have an effect on long-term angiogenesis and EC apoptosis. Double labeled immunostaining of CD31 and BrdU was performed to evaluate angiogenesis at day 14 post-stroke. Compared to the sham group, neovascularization in the ischemic boundary zone was observed in the vehicle and FTY720 treatment groups (Fig. 4A ). CD31+BrdU+ cell counts and the percentage of CD31+BrdU+ cells were significantly elevated in the FTY720-treated group compared to the vehicle group; the number of CD31+ cells in the FTY720-treated group was greater than those in the vehicle group, and these counts were both less than that in the sham group (Fig.   4B ). These results indicated that FTY720 promoted angiogenesis in the ischemic boundary zone during PT stroke.
Promotion of angiogenesis was due to modulation of microglial M2 polarization by
FTY720 in vitro S1PR1 antagonists and agonists exert several effects on angiogenesis under different conditions (Fujii et al., 2012; Gaengel et al., 2012; Iwasawa et al., 2018) . Expression of adhesion molecules on the cerebral endothelium and endothelial activation are inhibited by FTY720 . To investigate whether enhanced angiogenesis in the peri-infarct area was due to FTY720 itself directly, or the microglial anti-inflammatory state mediated by FTY720, the tube-forming capacity of primary ECs subjected to OGD was assessed when incubated with microglial supernatants under different interventions (Fig. 5A,B) .
Tube counts and tube length were elevated in microglia cultured with LPS, IFN-γ, and FTY720 together, compared to cells in the control and LPS + IFN-γ alone groups, though the increase was not higher than that in the IL-4 group. To identify whether FTY720 treatment had a direct pro-angiogenic effect on primary ECs, we cultured microglia with LPS + IFN-γ alone, and then the microglial supernatants were added to ECs together with FTY720 ((LPS + IFN-γ) + FTY720 group). Tube formation results revealed no significant distinction between the LPS + IFN-γ group given or not given FTY720 ( Fig. 5A,B ). Furthermore, the flow cytometry results showed that there was no significant difference among the LPS + IFN-γ, LPS + IFN-γ + FTY720, and (LPS + IFN-γ) + FTY720 groups, indicating that changes in microglial polarization mediated by FTY720 had no influence on apoptosis of ECs ( Fig. 5C ).
Overall, our results imply that enhanced angiogenesis in the ischemic boundary zone after FTY720 treatment might be not due to FTY720 itself but may be attributed to improvements in the microenvironment of vessel growth when the microglial phenotype is transformed towards an anti-inflammatory state by FTY720.
Discussion
The results of the present study demonstrated that FTY720 significantly decreased neuron loss, improved motor function deficits, skewed the microglial polarization state toward an anti-inflammatory phenotype, and promoted angiogenesis. These effects resulted in long-term neuroprotection against PT ischemic stroke.
One of the fundamental mechanisms of FTY720's neuroprotection was that enhanced angiogenesis in the ischemic boundary zone after FTY720 treatment might be partially due to improvements in the microenvironment of vessel growth when the microglial phenotype was transformed towards an anti-inflammatory state by FTY720. Several researchers reported that FTY720 treatment attenuated post-ischemic microglial activation, and neutrophil and lymphocyte infiltration . Liu et al. (Liu et al., 2013 ) performed a meta-analysis of the efficacy of FTY720 in animal models of stroke and showed that it diminished the infarct volume and improved the functional outcome.
Based on our experiments, infarct volume reached its maximal level at 1 day after PT stroke, which is consistent with results from experiments using the MCAO model (Liu and McCullough, 2011) . Neuronal protection lasted for 14 days. Most studies have attributed the short-term neuroprotective effect of FTY720 to increased BBB stability and decreased neutrophil infiltration (Kraft et al., 2013; . This short-term neuroprotection was mostly limited in 7 days post-stroke. However, little was known about long-term neuroprotection and the underlying mechanisms of FTY720 in ischemic stroke models. This raised the question of whether a longer-term protection existed. Recently, we reported that FTY720 protected against chronic ischemic white matter damage by modulating microglia toward M2 polarization via the signal transducer and activator of transcription 3 pathway . The present study confirmed that FTY720 stimulated microglia toward M2 polarization after PT stroke and daily treatment still had protection against ischemic brain damage until day 14. The process of gradually enhanced microglial activation and polarization to the M2 type was persistent when FTY720 was administered daily; at day 14, the ischemic lesion tended to be stable and inflammation had dissipated.
FTY720 is an anti-inflammatory S1PR modulator, mainly targeting S1PR1 and S1PR3-5 (O'Sullivan and Dev, 2013) . Interestingly, the effect of S1PR1 on angiogenesis is controversial. Konstantin et al. (Gaengel et al., 2012) found that the loss of S1PR1 in mice led to angiogenic hypersprouting. Specifically, the S1PR1-specific antagonist, (R)-W146, caused endothelial hypersprouting in the postnatal retina while the S1PR1-specific agonist, SEW2871, led to the formation of fewer, longer, and less branched sprouts. However, other studies demonstrated that an S1PR1-selective antagonist inhibited angiogenesis (Fujii et al., 2012) . Furthermore, the S1PR1-activator, SEW2871, enhanced leptomeningeal collateral circulation via endothelial NOS phosphorylation and promoted post-ischemic angiogenesis with reinforced BBB integrity in a mouse model of acute ischemic stroke (Iwasawa et al., 2018) .
FTY720 is not S1PR1-specific, and studies focused on S1PR3-5 are fewer than those on S1PR1. Mousseau et al. (Mousseau et al., 2012) demonstrated that FTY720 inhibited platelet-derived growth factor-B-induced migration of vascular smooth muscle cells by down-regulating the S1PR1/S1PR3 pathway. In addition, stimulation of S1PR5 with A-971432, a selective agonist, preserved BBB integrity and exerted a therapeutic effect in an animal model of Huntington's disease (Di Pardo et al., 2018) . The selective S1PR5 antagonist, BIO-027223, was used to show that S1PR5 participated in the human natural killer cell response to sphingosine 1-phosphate (Drouillard et al., 2018) . However, the effect of S1PR4 on angiogenesis has remained unclear. Our results implied that the ability of FTY720 to protect against ischemic stroke was probably mediated by FTY720-induced microglial polarization toward the M2 phenotype, not by a direct effect of FTY720 on ECs. stroke, the short-term effect of FTY720 treatment is mediated by a reduction of the pro-inflammatory interaction of lymphocytes with ECs and platelets, stabilization of BBB integrity, and blockade of neutrophil recruitment . FTY720 may protect the vasculature by reducing leukocyte adhesion secondary to altering endothelial adhesion molecule expression . For the long-term effect of FTY720 after cerebral ischemia, it could enhance angiogenesis through modulation of the microglial M2 phenotype.
Our research had several limitations. First, experiments in vivo cannot show that direct effects of fingolimod on microglia are responsible for enhanced angiogenesis, though this possibility was examined in vitro experiments. Mice with conditional gene knockout of a gene, such as tissue-specific S1PR1, might be used for this in future studies. Second, some researchers have deemed simple division of microglial changes by M1/M2 polarization inaccurate, especially for certain diseases. Ransohoff complied and analyzed genome-wide expression profiles of microglia from animal models of disease ex vivo (Ransohoff, 2016) . This is a better but costly way to assess microglial changes; a compromise would be to assess more microglial-specific markers such as some cytokines like IL-1β, IL-23, TNF-α, IL-10 and TGF-β to increase the reliability of experiments. A multi-dimensional evaluation of microglia would also be meaningful. Third, experiments to determine the mechanisms of short-term neuroprotection of fingolimod, such as assessment of BBB stability, discription of microhemorrhage, neutrophil infiltration (Prager et al., 2015) and microglial phagocytosis, have been insufficient. The present study suggested that FTY720 might be a potential drug for treating acute ischemic stroke, both in short-and long-term situations, due to its vasculo-protection and collateral circulation promotion effects, respectively. However, more investigations need to be performed to verify its utility.
Methods and materials
In vivo
PT cortical ischemic damage
Male wild-type C57BL/6 mice were used in this study. All mice were provided by the To induce PT stroke, rose bengal (Sigma-Aldrich, USA), a photosensitive dye, was dissolved in sterile saline at a concentration of 10 mg/ml, and 0.1 ml was injected intraperitoneally 5 min before illumination. PT cortical ischemia was elicited in mice anesthetized via inhalation of 3.5% isoflurane and maintained by inhalation of 1.0-2.0% isoflurane in 70% N 2 and 30% O 2 by a facemask. Body temperature was maintained at 37.0 ± 0.5°C with a heating blanket.
For the PT surgical procedure, bregma and lambda points were identified after a mid-scalp incision. Then, a fiber optic bundle of a cold light source (KL1500 LCD, Carl Zeiss, Germany) with a 4-mm aperture was centered using a micromanipulator at 2-mm right lateral to the bregma. The brain was illuminated through the intact skull for 15 min.
FTY720 treatment FTY720 (0.3 mg/kg; Cayman Chemical Company, USA) was dissolved in phosphate-buffered saline and administered intraperitoneally for 1, 7, or 14 consecutive days.
The first fingolimod dose was given 24h post-injury. The dose and duration of FTY720 was selected based on our preliminary experiments and previous studies .
Behavioral assessment
Modified neurological severity score assessment, as described previously (Chen et al., 2001) , was performed from days 1 to 14 post-stroke by investigators blinded to the different groups.
The results are presented as mean±SD in graphs
Nissl staining
Sections of identical lesions in different groups were stained with 0.1% toluidine blue, dehydrated, mounted with neutral balsam, and covered with a coverslip. Five fields were chosen randomly from the ischemic boundary zone and viewed at 200× magnification under a light microscope (Olympus, Japan).
Immunofluorescence staining
At 1, 7, and 14 days after ischemia, animals were perfused with 4% paraformaldehyde in 0.1 M phosphate buffer. Brain tissues were post-fixed for 4-6 h and immersed in gradient sucrose solutions for 24-48 h at 4°C until they sank. Sections were cut (20-µm thickness) with a cryostat and prepared for immunostaining. The slides were blocked with 1% bovine serum albumin containing 0.3% Triton X-100 for 1 h. Sections were then incubated overnight at 4°C with the following primary antibodies: rabbit anti-mouse Iba1 (1:200, Wako, Japan), rat anti-mouse CD16/32 (1:50, BD Biosciences, USA), and goat anti-mouse CD206 (1:200, R&D Systems, USA) . The sections were then incubated for 1 h at room temperature with their respective secondary fluorescent antibodies (1:500, Jackson ImmunoResearch, USA) to visualize the primary antibodies. Images were acquired with a confocal microscope (Olympus).
Bromodeoxyuridine (BrdU) incorporation and detection
To identify the proliferation of ECs after ischemia, mice were injected with 200 mg/kg BrdU (Sigma-Aldrich) intraperitoneally once a day for 5 consecutive days before being sacrificed for the experiments. Brain sections from BrdU-injected mice were treated to permeabilize the tissue and denature the DNA, and were then incubated overnight with the following primary antibodies: rabbit anti-mouse CD31 (1:50, Abcam, USA) and mouse monoclonal anti-BrdU (1:100, Abcam). The secondary antibodies (1: 500 dilutions) were Alexa 488-labeled goat anti-mouse for BrdU and Alexa 594-labeled goat anti-rabbit for CD31. For counting BrdU-labeled cells, three coronal sections per animal were analyzed with five randomly selected images within each area of interest (peri-infarct zone). The total numbers of BrdU+ and CD31+ cells, and BrdU+ and CD31+ cell percentages per field were determined.
Western blotting
Brain tissue samples were lysed with lysis buffer (200 mM Tris [pH8.0], 150 mM NaCl, 2 mM EDTA, 1 mM NaF, 1% NP40, 1 mM phenylmethylsulfonyl fluoride, and protease inhibitor cocktail). The total protein concentration in the lysates was determined using the Bradford protein assay and 30 μg of protein from each sample was separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, then transferred to a polyvinylidene difluoride membrane. After transfer, the membranes were incubated with 5% skim milk in tris-buffered saline/0.1% Tween 20 for 1 h, followed by incubation overnight at 4°C with primary antibodies against CD16, inducible nitric oxide synthase (iNOS), CD206, arginase-1 (Arg-1), and β-actin. The blots were washed and incubated with appropriate horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology, USA) for 1 h. All bands were detected using an enhanced chemiluminescence kit (Pierce Biotech, USA), and imaged using an Image Quant LAS-4000 system (GE Healthcare Life Science, Sweden).
Representative results of at least five experiments are shown for the western blot assays. Blot intensities were semi-quantified using ImageJ software. β-actin was used as the internal control and the data processor was blind to the treatment groups.
In vitro
Cell culture
Microglia cells and brain microvascular ECs were obtained for primary cell culture from newly born and 7-10-day-old wild-type mice, respectively, as described previously (Hanisch et al., 1997) . Isolated microglia were divided into four groups: untreated (control), lipopolysaccharide (LPS) (100 ng/ml) + interferon (IFN)-γ (20 ng/ml), LPS (100 ng/ml) + IFN-γ (20 ng/ml) + FTY720 (25 ng/ml), and interleukin (IL)-4 (20 ng/ml). Cells were incubated for 24 h and the supernatants were collected separately.
We established an oxygen-glucose deprivation (OGD) murine cell model to mimic ischemic stroke by exposing brain microvascular ECs to OGD for 4 h, followed by reoxygenation for 24 h. At the same time, the supernatants from six treatment groups were added to the EC medium at a ratio of 1:1. This included the four microglia groups plus two more: control" group (ECs with their original medium) and (LPS + IFN-γ) + FTY720 group (FTY720 was added directly to the EC medium, not to the microglia cell medium), to identify any confounding effect of FTY720 on ECs.
Tube formation assay
After treatment, ECs (1.0 × 10 4 cells/well) were seeded on a thin layer of Matrigel (BD Biosciences) in 96-well plates for 4 h. Images were acquired by an inverted microscope (Axiovert 40, Carl Zeiss, Germany) to measure the structures. Tube length, tube counts, and branching points were quantified using Image J software (National Institutes of Health, USA).
For quantification, we photographed four randomly selected visual fields and averaged the values obtained. Three independent experiments were performed in triplicate.
Flow cytometry assay
Flow cytometry was performed to detect cell apoptosis using an Annexin V-FITC and propidium iodide double staining kit (KeyGen, China) according to the manufacturer's instructions. Briefly, after treatments as indicated, ECs were collected and impurities removed by centrifugation two times at 167.7xg for 5 min. The ECs were then resuspended in 19 500 μl of binding buffer and incubated with 5 μl FITC Annexin V and 5 μl propidium iodide, followed by gently vortexing for 15 min at room temperature in the dark. Samples were analyzed using a FACSCalibur flow cytometer within 1 h (BD Biosciences).
Western blotting
Western blotting analysis was performed as described previously. Briefly, the treated microglia cells were washed twice with ice-cold phosphate-buffered saline and lysed in radioimmunoprecipitation assay buffer (Google Biotechnology, USA) containing protease inhibitor cocktail (Roche, Switzerland). The protein concentration of cell lysates was determined by a bicinchoninic acid protein assay kit (Google Biotechnology). Samples were subjected to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, then transferred to a nitrocellulose membrane (Boster, USA).The nitrocellulose membrane was blocked with 5% non-fat milk and incubated with antibodies recognizing iNOS (1:500, ABclonal, USA), CD16 (1:500, Boster), CD206 (1:1000, BD Biosciences), and Arg-1 (1:1000, ABclonal) at 4°C overnight. Then, the blots were incubated with a horseradish peroxidase-conjugated secondary antibody (1:1000, Boster) for 1 h at room temperature. An enhanced chemiluminescence detection kit (Thermo Fisher Scientific, USA) was used to detect signals.
Representative results of at least five western blot assays are shown. Blot intensities were semi-quantified using ImageJ software. β-actin was used as the internal control and the data processor was blind to the treatment groups.
Quantification and statistical analysis 20
All cell counts and intensity analyses were performed blinded to the experimental treatment.
Two independent researchers counted cells. They were both blind to the treatment groups and counted separately. The counts were were averaged, and these averages were used in the statistical analyses. Data are expressed as means ± SEM. All statistical tests were performed using Prism software (GraphPad, USA). The Kolmogorov-Smirnov method was used to test normality, followed by application of the SNK test. All original data were normally distributed. And repeated measures ANOVA was used for the behavioral test data. As for other analyses, a multivariate ANOVA was applied first and then an SKN test was used to verify results for each pair. P < 0.05 was considered statistically significant. C. Behavioral test modified neurological severity scores of mice are assessed 14 days after PT ischemia (n = 9 both for vehicle and FTY720-treatment groups). Compared to the vehicle group, the modified neurological severity score is significantly decreased in the FTY720 treatment group. This suggests that murine motor deficits improve gradually, mainly in the first 8 days (*P < 0.05 vs. vehicle), and remain steady till day 14.
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Figure 5
25 Promotion of angiogenesis is due to modulation of microglial M2 polarization by FTY720 in vitro.
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